Abstract
The introduction of effective and potent treatments for human immunodeficiency virus (HIV) infection resulted in prolonged survival and better quality of life of HIV-infected patients. However, the longer survival and the anti-HIV medication side effects caused the emergence of new clinical issues, such as the increase in cardiovascular risk, favored by multiple factors, partly related to HIV infection itself, partly to the anti-HIV molecules. HIV infection itself may affect cardiovascular risk through chronic inflammation induced by uncontrolled viral replication, whereas long-term antiretroviral therapy may increase the cardiovascular risk through several mechanisms. Thus, due to the multiple and conflicting causes of cardiovascular disorders in HIV-infected patients, clinicians should take into consideration all modifiable risk factors, in order to implement an effective prevention of this clinical issue.
Keywords: HIV infection, AIDS, atherosclerosis, cardiovascular risk, antiretroviral therapy, lipids, endothelium, human immunodeficiency virus (HIV), anti-HIVmedication, chronic inflammation, uncontrolled viral replication, efficacy of the combination antiretroviral treatment (cART), dyslipidemia, insulinresistance and endothelial damage
Current Pharmaceutical Biotechnology
Title: HIV and Accelerated Atheroprogression: Role of Antiretroviral Therapy
Volume: 13 Issue: 1
Author(s): Antonio Di Biagio, Valerio Del Bono, Raffaella Rosso and Claudio Viscoli
Affiliation:
Keywords: HIV infection, AIDS, atherosclerosis, cardiovascular risk, antiretroviral therapy, lipids, endothelium, human immunodeficiency virus (HIV), anti-HIVmedication, chronic inflammation, uncontrolled viral replication, efficacy of the combination antiretroviral treatment (cART), dyslipidemia, insulinresistance and endothelial damage
Abstract: The introduction of effective and potent treatments for human immunodeficiency virus (HIV) infection resulted in prolonged survival and better quality of life of HIV-infected patients. However, the longer survival and the anti-HIV medication side effects caused the emergence of new clinical issues, such as the increase in cardiovascular risk, favored by multiple factors, partly related to HIV infection itself, partly to the anti-HIV molecules. HIV infection itself may affect cardiovascular risk through chronic inflammation induced by uncontrolled viral replication, whereas long-term antiretroviral therapy may increase the cardiovascular risk through several mechanisms. Thus, due to the multiple and conflicting causes of cardiovascular disorders in HIV-infected patients, clinicians should take into consideration all modifiable risk factors, in order to implement an effective prevention of this clinical issue.
Export Options
About this article
Cite this article as:
Di Biagio Antonio, Del Bono Valerio, Rosso Raffaella and Viscoli Claudio, HIV and Accelerated Atheroprogression: Role of Antiretroviral Therapy, Current Pharmaceutical Biotechnology 2012; 13 (1) . https://dx.doi.org/10.2174/138920112798868520
DOI https://dx.doi.org/10.2174/138920112798868520 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and LDL Lowering in the Contemporary Management of Dyslipidemia
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacogenetics and Pharmacotherapy of Military Personnel Suffering from Post-traumatic Stress Disorder
Current Neuropharmacology Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology Gender Differences in the Risk of Adverse Outcomes After Incident Diabetic Foot Hospitalization: A Population Cohort Study
Current Diabetes Reviews Materials Etiquette and Complement Responses
Current Bionanotechnology (Discontinued) Radiopharmaceutical: Revolutionary Agents for Diagnosis
Current Radiopharmaceuticals Application of High-Throughput, Molecular-Targeted Screening to Anticancer Drug Discovery
Current Topics in Medicinal Chemistry Neutrophil Cell Count is Related to Hypertension in Workers: A Cross- Sectional Study
Vascular Disease Prevention (Discontinued) Molecular Determinants of the Cardiometabolic Phenotype
Endocrine, Metabolic & Immune Disorders - Drug Targets Subject Index To Volume 7
Current Drug Targets COVID-19 Infection in Pregnancy: A Review
Infectious Disorders - Drug Targets Chronic Immune Stimulation Correlates with Reduced Phenylalanine Turnover
Current Drug Metabolism Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition Prader-Willi Syndrome: Clinical Genetics and Diagnostic Aspects with Treatment Approaches
Current Pediatric Reviews Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety Epidemiology of Low Dose Aspirin Damage in the Lower Gastrointestinal Tract
Current Pharmaceutical Design Tailoring Antiplatelet Therapy: A Step Toward Individualized Therapy to Improve Clinical Outcome?
Current Pharmaceutical Design Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Induced Dyspepsia
Current Pharmaceutical Design Action Mechanism of Antihistamines and the New Antihistamines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Editorial (Thematic Issue: Phytochemicals, Intracellular Signalling Pathways and Anti-Cancer Effects)
Anti-Cancer Agents in Medicinal Chemistry